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A 62-year-old male was diagnosed with blastic plasmacytoid dendritic cell neoplasm 
(BPDCN) with a MYC rearrangement. Four months after the first unrelated bone 
marrow transplantation (BMT), he developed the relapsed BPDCN. After the 
achievement of partial remission following re-induction therapy, he underwent a second 
BMT from another unrelated donor, and experienced complete remission with grade II 
acute graft-versus-host disease and moderate chronic graft-versus-host disease. He 
remains alive in complete remission more than 71 months after the second BMT. These 
results suggested that donor change at the second transplantation may represent a 















Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive 
malignant disorder derived from the precursors of plasmacytoid dendritic cells with a 
high frequency of cutaneous and bone marrow involvement [1,2,7]. Patients with 
BPDCN have a poor prognosis; the median overall survival after chemotherapy has 
been 7.1 to 11.0 months [1, 2]. Previous reports showed that allogeneic hematopoietic 
stem cell transplantation (allo-HSCT) or autologous-HSCT are promising modalities 
that provide durable remission for BPDCN patients, with median overall survival after 
transplantation ranging from 22.7 to 53.5 months [1, 3, 4]. Therefore, allo-HSCT and 
autologous-HSCT should be considered as a therapeutic option for eligible patients.  
However, the relapse rate after allo-HSCT is approximately 30% [3, 4], and relapsed 
patients have an extremely poor prognosis. Treatment options for the relapsed disease 
after allo-HSCT include withdrawal of immunosuppressants, donor lymphocyte 
infusion, and chemotherapy [5], but there are few reports describing the feasibility of a 
second allo-HSCT. 
We here report a patient with BPDCN who achieved long-term remission after a 
















A 62-year-old male presented with a cutaneous tumor on the left arm and 
lymphadenopathy in the left axilla. Skin biopsy showed a diffuse infiltration of tumor 
cells with immunoblastoid cytomorphology [6]. The cells were positive for CD4, 
CD123, TCL1, and MYC and partly positive for CD56 (Figure 1A-G); but negative for 
CD3, CD20, CD79a, terminal deoxynucleotidyl transferase (TdT), myeloperoxidase 
(MPO), CD34, and the Epstein-Barr encoding region. In split fluorescence in situ 
hybridization (FISH) assay [10], tumor cells were positive for 8q24 (MYC locus) 
rearrangement but negative for SUPT3H and MYB rearrangements (Figure 2). The 
present patient was diagnosed with BPDCN according to the diagnostic criteria 
proposed by Julia et al. [7]. Peripheral blood yielded a hemoglobin level of 14.4 g/dL, a 
leukocyte count of 6.6 ×10
3
/μL and a platelet count of 13.5 ×10
4
/μL. Bone marrow 
examination showed 92% blast cells (Figure 1H), of which MPO activity was not 
detected by the diaminobenzidine method. Flow cytometry analysis revealed that the 
leukemic cells were positive for CD4, CD33, CD123, interleukin-3 receptor, human 
leukocyte antigen (HLA)-DR, and CD45RA, partly positive for CD56 and negative for 
TdT and cytoplasmic MPO. G-banding analysis showed del(13)(q12q22) in 7 out of 16 














polymerase chain reaction (PCR) analysis and immunoglobulin heavy-chain genes by 
Southern blotting analysis were not detected. These findings confirmed bone marrow 
involvement of BPDCN. The induction chemotherapy was initiated with daunorubicin 
50 mg/m
2
 daily for 5 days and cytarabine 100 mg/m
2
 daily for 7 days, resulting in 
complete hematological remission (CR). Subsequently, he received 2 courses of 
consolidation chemotherapy. The patient did not have a related donor who was 
serologically HLA-matched. Thus, he was transplanted with unrelated bone marrow 
from a male donor (total nucleated cell dose, 3.4×10
8
 cells/kg; genotypically matched 
for HLA-A, -B, -Cw, and -DR1) from the Japan Marrow Donor Program using a RIC 
regimen with total body irradiation (TBI) 2 Gy / 1 fraction, fludarabine (Flu) 125 mg/m
2
, 
and melphalan (Mel) 80 mg/m
2
. A combination of tacrolimus (Tac) and short-term 
methotrexate (sMTX) was used as graft-versus-host disease (GVHD) prophylaxis. 
Neutrophil engraftment (absolute neutrophil count of at least >0.5 ×10
9
/L for 3 
consecutive points) and platelet recovery (platelet count of >50 ×10
9
/l without 
transfusion for 3 consecutive points) were obtained on days +15 and +30 after 
transplantation, respectively. He maintained CR without any symptoms of GVHD.  
Four months after the initial transplantation, he developed two cutaneous tumors on his 














showed no evidence of relapse, which confirmed extramedullary relapse of BPDCN. 
Despite the cessation of Tac, lymphadenopathy in the left inguinal was noted. At day 
180 after allo-HSCT, bone marrow examination revealed 10% leukemic cells, and short 
tandem repeat DNA analysis showed 5.5% recipient-type cells at day 180, indicating a 
progression to hematological relapse of BPDCN. He achieved partial remission after 1 
course of re-induction chemotherapy with daily cyclophosphamide 600 mg/m
2
 on day 1, 
vincristine 1.3 mg/m
2
 on days 1, 8, 15, 22, doxorubicin 20 mg/m
2
 on days 1 to 3, 
prednisolone 60 mg/body po on days 1 to 7 (then tapered for 28 days) and 
L-asparaginase 2000 IU/m
2
 div on days 11, 13, 18, 21. The patient was transplanted 
with HLA-matched unrelated male bone marrow (total nucleated cell dose, 2.3×10
8
 
cells/kg; genotypically matched for HLA-A, -B, -Cw and -DR1) followed by a RIC 
regimen with Flu 30 mg/m
2
 daily for 5 days, intravenous busulfan (BU) 3.2 mg/kg daily 
for 2 days, and TBI 2 Gy / 1 fraction. Tac and sMTX were administered as prophylaxis 
against GVHD. Ten days after the second transplantation (before neutrophil 
engraftment), he presented with stridor due to severe laryngeal irritation, and underwent 
mechanical ventilation. Neutrophil engraftment and platelet recovery were achieved on 
days +21 and +127 after the second transplantation, respectively. He achieved the 














acute GVHD with stage 2 skin involvement 48 days after transplantation, but did not 
require additional immunosuppressive treatment, such as systemic administration of 
corticosteroid. He presented lichen planus-like features in the skin and oral mucosa due 
to moderate chronic GVHD. He started anti-androgen therapy for localized prostate 
cancer at day +1525. During anti-androgen therapy, he did not experience any symptom 
of relapse disease of BPDCN. Furthermore, chronic GVHD in oral mucosa and skin 
persisted without progression in any other organ, and a lymphocyte count was 
maintained between 3.01 and 4.41 × 10
9
/L. The withdrawal of immunosuppressants was 
performed on day +1748. He was alive without any symptom of relapse more than 71 
months after the second allo-HSCT. 
 
Discussion 
We treated a BPDCN patient who was maintained in CR for more than 5 years after a 
second allo-HSCT. Use of a new donor for the second allo-HSCT was reported to be a 
valid option in patients who developed relapse of acute leukemia after the first 
allo-HSCT [8]. To the best of our knowledge, this is the first report of the feasibility of 
using a different donor for a second allo-HSCT for a relapsed BPDCN patient. 














after the first unrelated allo-HSCT in the present case. One interesting finding was that 
no symptom of GVHD was observed after the first allo-HSCT, but acute and chronic 
GVHD developed after the second allo-HSCT. Based on the facts previously reported 
about graft-versus-leukemia effect together with the occurrence of GVHD for several 
other hematological malignancies [9, 10], we speculate that the potent 
graft-versus-tumor effect for BPDCN was enhanced by the development of GVHD 
following the second allo-HSCT. Thus, it is possible that avoidance of additional 
treatment for active GVHD preserved the potential graft-versus-BPDCN effect in the 
present case. In this regard, donor change at the second allo-HSCT would be a 
considerable option for relapsed BPDCN patients without a history of GVHD after their 
first allo-HSCT. 
The present case suggested that the application of a second allo-HSCT should be 
considered for BPDCN patients if the patient is eligible and a suitable donor is available. 
For such patients, a RIC regimen would be suitable in order to minimize life-threatening 
complications. Aoki et al. reported promising results of allo-HSCT using a RIC regimen 
for chemosentivitive BPDCN [4]. However, our patient experienced severe laryngeal 
irritation early after the second allo-HSCT. Thus, careful management is needed for 















A recent retrospective study showed that 8q24 rearrangement and subsequent MYC 
expression in BPDCN correlated with a poor prognosis [6], and a standard therapeutic 
strategy is not yet established. Therefore, it would be of interest to determine whether 
allo-HSCT utilizing a graft-versus-tumor effect could overcome the negative impact of 
8q24 rearrangement and subsequent MYC expression in BPDCN. Considering the 
promising experimental results of novel molecular-targeting agents for BPDCN with 
MYC rearrangement [6], the efficacy of sequential treatment with such agents and 
allo-HSCT using RIC should be investigated in future studies. 
In summary, our results suggested that donor change at a second allo-HSCT might 
have a considerable therapeutic benefit for relapsed BPDCN with MYC rearrangement. 
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Figure 1. Pathological features of a cutaneous tumor and microscopic features of 
blastoid cells in bone marrow. 
Skin biopsy showed diffuse infiltration of tumor cells with immunoblastoid cytology in 
the dermis (H-E staining: A, ×100; B, ×400). Immunohistochemically, the infiltrating 
immunoblastoid cells were positive for CD4 (C, ×200), CD123 (D, ×200), TCL1 
(E, ×200), and MYC (F, ×400) and partly positive for CD56 (G, ×200). Bone marrow 


















Figure 2. Split fluorescence in situ hybridization assessment of a cutaneous tumor. 
Tumor cells were positive for an 8q24 (MYC locus) rearrangement using Vysis LSI 
IGH-MAF dual colour dual fusion translocation probe (A), but negative for 
SUPT3H (B) and MYB rearrangements (C). 
 
